Medicine and Dentistry
Nivolumab
100%
Ipilimumab
100%
Metastatic Melanoma
50%
Immune Checkpoint Inhibitor
50%
Melanoma
50%
Treatment Duration
33%
Event Free Survival
30%
Neoplasm
26%
Combination Therapy
25%
Immune-Related Adverse Events
25%
Immunotherapy
20%
Adjuvant Therapy
20%
Survival Time
10%
Adverse Event
10%
Recurrence Free Survival
10%
Systemic Therapy
10%
Quality of Life
8%
Nodular Melanoma
8%
Arm
8%
Overall Survival
8%
Maintenance Therapy
8%
Disease Exacerbation
8%
Prognostic Factor
8%
Diseases
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
50%
Metastatic Melanoma
50%
Ipilimumab
50%
Immune Checkpoint Inhibitor
50%
Antibiotic Agent
50%
Mycophenolic Acid
50%
Adverse Event
25%
Combination Therapy
25%
Neoplasm
16%
Therapeutic Drug Monitoring
14%
Melanoma
8%
Disease Exacerbation
8%
Overall Survival
8%
Disease
8%
Antibiotics
7%
Glucuronide
7%
Intestine Flora
7%
Pharmacokinetics
7%
Beta Glucuronidase
7%
Immunosuppressive Agent
7%